The Relative Importance of Clinical, Economic, Patient Values and Feasibility Criteria in Cancer Drug Reimbursement in Canada: A Revealed Preferences Analysis of Recommendations of the Pan-Canadian Oncology Drug Review 2011–2017

Variation in Health Technology Assessment and Reimbursement Processes in Europe

(2017) Ronald L Akehurst et al.   VALUE IN HEALTH

Health benefit assessment of pharmaceuticals: An international comparison of decisions from Germany, England, Scotland and Australia

(2016) Katharina Elisabeth Fischer et al.   HEALTH POLICY

Eight-year experience of using HTA in drug reimbursement: South Korea

(2016) Eun-Young Bae et al.   HEALTH POLICY

Impact of patient outcomes and cost aspects on reimbursement recommendations in Poland in 2012–2014

(2016) Krzysztof Piotr Malinowski et al.   HEALTH POLICY

A comparative study of drug listing recommendations and the decision-making process in Australia, the Netherlands, Sweden, and the UK

(2016) Sebastian Salas-Vega et al.   HEALTH POLICY

Reimbursement of Targeted Cancer Therapies Within 3 Different European Health Care Systems

(2015) Jovan Mihajlović et al.   CLINICAL THERAPEUTICS

A comparative study of the role of disease severity in drug reimbursement decision making in four European countries

(2015) Margreet Franken et al.   HEALTH POLICY

Same drugs, valued differently? Comparing comparators and methods used in reimbursement recommendations in Australia, Canada, and Korea

(2015) Green Bae et al.   HEALTH POLICY

Does it Matter Whether Canada’s Separate Health Technology Assessment Process for Cancer Drugs has an Economic Rationale?

(2015) Jeffrey S. Hoch et al.   PHARMACOECONOMICS

The Silence in Hoch et al.’s Commentary about the Rationale for and Objective(s) of Canada’s Separate HTA Process for Cancer Drugs: The Importance of Transparency and Accountability when Allocating Taxpayers’ Dollars

(2015) Heather McDonald et al.   PHARMACOECONOMICS

Reimbursement Decisions for Pharmaceuticals in Sweden: The Impact of Disease Severity and Cost Effectiveness

(2015) Mikael Svensson et al.   PHARMACOECONOMICS

Which Factors Enhance Positive Drug Reimbursement Recommendation in Scotland? A Retrospective Analysis 2006–2013

(2015) Mata Charokopou et al.   VALUE IN HEALTH

Predictors for reimbursement of oncology drugs in Belgium between 2002 and 2013

(2015) Kim Pauwels et al.   Expert Review of Pharmacoeconomics & Outcomes Research

The Influence of Cost-Effectiveness and Other Factors on Nice Decisions

(2014) Helen Dakin et al.   HEALTH ECONOMICS

Is There an Economic Rationale for Cancer Drugs to Have a Separate Reimbursement Review Process for Resource Allocation Purposes?

(2014) Heather McDonald et al.   PHARMACOECONOMICS

A Synthesis of Drug Reimbursement Decision-Making Processes in Organisation for Economic Co-operation and Development Countries

(2014) Lianne Barnieh et al.   VALUE IN HEALTH

Unravelling Drug Reimbursement Outcomes: A Comparative Study of the Role of Pharmacoeconomic Evidence in Dutch and Swedish Reimbursement Decision Making

(2013) Margreet Franken et al.   PHARMACOECONOMICS

Reimbursement Decisions of the All Wales Medicines Strategy Group

(2012) Warren G. Linley et al.   PHARMACOECONOMICS

Using Effectiveness and Cost-effectiveness to Make Drug Coverage Decisions

(2009) Fiona M. Clement et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Cost-effectiveness considerations at NICE

(2008) Michael Rawlins et al.   LANCET

The Role of Value for Money in Public Insurance Coverage Decisions for Drugs in Australia: A Retrospective Analysis 1994-2004

(2008) Anthony H. Harris et al.   MEDICAL DECISION MAKING

The Role of Economic Evidence in Canadian Oncology Reimbursement Decision-Making: To Lambda and Beyond

(2008) Angela Rocchi et al.   VALUE IN HEALTH